Phenotypes Associated with This Genotype

Genotype
MGI:4889055

• Allelic Composition: Foxm1^tm1Rhc/Foxm1^tm1Rhc; Tg(SFTPC-rtTA)5Jaw/0; Tg(tetO-cre)1Jaw/0
• Genetic Background: involves: 129 * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

neonatal lethality, incomplete penetrance ( J:142246 )

• 82% of mice treated with doxycycline from E7.5 to E14.5 die within the first 24 hrs after birth due to respiratory failure

respiratory system

respiratory system phenotype ( J:142246 )

N • mice treated with doxycycline during postnatal period P3-P30 show no differences in overall lung morphology or expression of epithelial marker proteins relative to control littermates

pulmonary vascular congestion ( J:142246 )

• 82% of mice treated with doxycycline from E7.5 to E14.5 display pulmonary congestion

abnormal lung development ( J:142246 )

• mice treated with doxycycline from E7.5 to E14.5 display delayed lung maturation, as shown by reduced lung sacculation and mesenchymal thickening prior to birth (E17.5 and E18.5)

• however, branching morphogenesis and proliferation of distal respiratory epithelial cells is normal at E15.5 and E18.5

• no vascular abnormalities are detected at E18.5, as shown by normal Pecam-1 staining

• differentiation of ciliated and Clara cells in conducting airways remains normal

abnormal lung saccule morphology ( J:142246 )

• mice treated with doxycycline from E7.5 to E14.5 display reduced lung sacculation prior to birth

• consistent with delayed lung maturation, peripheral lung tubules remain closed, unlike in control littermates

small lung saccule ( J:142246 )

• mice treated with doxycycline from E7.5 to E14.5 display smaller peripheral saccules at E17.5 and E18.5

thick lung-associated mesenchyme ( J:142246 )

• increased mesenchymal thickness prior to birth

abnormal pulmonary alveolus epithelial cell morphology ( J:142246 )

• mice treated with doxycycline from E7.5 to E14.5 show delayed differentiation of type I and type II epithelial cells

decreased type I pneumocyte number ( J:142246 )

• mice treated with doxycycline from E7.5 to E14.5 display reduced numbers of squamous type I epithelial cells

• however, type I epithelial cells appear ultrastructurally normal

abnormal type II pneumocyte morphology ( J:142246 )

small alveolar lamellar bodies ( J:142246 )

• mice treated with doxycycline from E7.5 to E14.5 show significantly smaller lamellar bodies in type II cells relative to control littermates

atelectasis ( J:142246 )

• mice treated with doxycycline from E7.5 to E14.5 display focal atelectasis

abnormal respiratory conducting tube morphology ( J:142246 )

• 82% of mice treated with doxycycline from E7.5 to E14.5 display pulmonary congestion, focal atelectasis, bronchial occlusion, and hyaline membranes lining terminal airways consistent with severe respiratory distress syndrome (RDS)

• ~18% of mice treated with doxycycline from E7.5 to E14.5 survive after birth and exhibit mild RDS with focal atelectasis

pulmonary hyaline membrane formation ( J:142246 )

• 82% of mice treated with doxycycline from E7.5 to E14.5 display hyaline membranes lining the terminal airways

respiratory distress ( J:142246 )

• 82% of mice treated with doxycycline from E7.5 to E14.5 display severe respiratory distress

respiratory failure ( J:142246 )

• 82% of mice treated with doxycycline from E7.5 to E14.5 die within the first 24 hrs after birth due to respiratory failure

decreased surfactant secretion ( J:142246 )

• mice treated with doxycycline from E7.5 to E14.5 show reduced pulmonary SP-A, SP-B, SP-C, and SP-D mRNA levels at E17.5 relative to control littermates

• SP-B mRNA is reduced to 40% of control values

cardiovascular system

pulmonary vascular congestion ( J:142246 )

• 82% of mice treated with doxycycline from E7.5 to E14.5 display pulmonary congestion